Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phibro Animal Health Corporation (Nasdaq: PAHC) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Phibro’s animal health, mineral nutrition, and performance products businesses, as well as its governance, capital structure, and risk disclosures.
Key documents for PAHC include annual reports on Form 10-K and quarterly reports on Form 10-Q, where Phibro presents audited and interim financial statements, segment information for Animal Health, Mineral Nutrition, and Performance Products, and management’s discussion of factors affecting net sales, gross profit, operating expenses, and tax rates. These reports also describe product categories such as medicated feed additives, nutritional specialty products, vaccines, mineral nutrition products, and performance products.
Current reports on Form 8-K are particularly useful for tracking material events. For Phibro, recent 8-K filings have covered quarterly and annual financial results, updates to financial guidance, dividend declarations on Class A and Class B common stock, and a planned leadership transition in which Jack C. Bendheim is expected to move to an Executive Chairman role and Daniel (Dani) Bendheim is expected to become Chief Executive Officer and President as of a specified effective date. Other 8-K items document stockholder meeting results, including votes on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
Phibro’s definitive proxy statement (DEF 14A) provides extensive detail on corporate governance, Board structure, executive compensation philosophy and programs, related party transactions, and security ownership of certain beneficial owners and management. It also explains the voting rights of Class A and Class B common stock and the matters presented at the annual meeting.
On Stock Titan, AI-powered tools can help summarize lengthy filings such as 10-Ks, 10-Qs, 8-Ks, and proxy statements for PAHC, highlighting segment performance, notable risk or governance disclosures, and key decisions by the Board and stockholders. Users can also review filings related to dividends and other corporate actions, and, where available, monitor insider and beneficial ownership information reported in SEC forms. Real-time updates from EDGAR ensure that new Phibro filings appear promptly, while AI-generated overviews make it easier to understand the implications of complex regulatory documents.
Phibro Animal Health (PAHC) insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI Co., LLC reported open-market sales totaling 14,080 shares of Class A Common Stock on March 30 and March 31 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices were about $53.54 and $54.31 per share on March 30 and about $53.87 and $54.35 per share on March 31. After these transactions, BFI Co., LLC holds 38,120 shares indirectly, while Bendheim directly holds 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corp (PAHC) filing shows The Vanguard Group filed Amendment No. 13 to its Schedule 13G/A stating it beneficially owns 0% of Phibro Animal Health Corp common stock as reported in the form. The amendment explains an internal realignment on 01/12/2026 that caused certain Vanguard subsidiaries and business divisions to report ownership separately.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity over which President and CEO Jack Bendheim exercises voting and dispositive power, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on March 24–26, 2026.
The weighted average sale prices ranged from about $52.8772 to $57.1702 per share. Following these indirect sales, BFI Co., LLC held 52,200 Class A shares, while Bendheim directly held 16,840 shares. The sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating they were pre-scheduled rather than discretionary.
Phibro Animal Health insider activity shows an entity associated with President and CEO Jack Bendheim selling Class A Common Stock. BFI Co., LLC sold a total of 22,880 shares in open-market transactions on March 17–19 at reported weighted average prices between $51.6590 and $53.6436 per share, under a Rule 10b5-1 trading plan adopted on December 11, 2025. Following these sales, BFI Co., LLC held 73,320 shares indirectly, while Jack Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.
Phibro Animal Health insider activity shows entity BFI Co., LLC, which is associated with President and CEO Jack Bendheim, converting and selling shares. BFI converted 100,000 shares of Class B Common Stock into the same number of Class A shares and then sold 5,280 Class A shares at a weighted average price of $48.91 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, indicating it was scheduled in advance. Following these transactions, BFI held 96,200 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares, and BFI continued to hold 19,596,034 Class B shares, which remain convertible into Class A on a one-for-one basis.
Phibro Animal Health Corporation submitted a Form 144 notice indicating proposed sales of Class A Common Stock by an affiliate, with multiple transactions listed through February 2026. The excerpt includes numerous brokered sell entries by BFI Co. LLC, including large single-day totals such as 58,042 shares and 49,280 shares.
The filing lists transaction dates and per‑trade share counts and proceeds; the excerpt does not state aggregate registered offering treatment or who receives proceeds.
Phibro Animal Health CorpBFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A common stock in open-market transactions from February 24–26, 2026, under a pre-established Rule 10b5-1 trading plan adopted on May 30, 2025.
The reported weighted-average sale prices for these trades were around $51–$54 per share, and the filing notes that some shares are held directly by Jack Bendheim while others are held indirectly through BFI Co., LLC.
BFI Co., LLC, an entity associated with Phibro Animal Health’s President and CEO Jack Bendheim, reported pre-planned open-market sales of 14,080 shares of Class A Common Stock under a Rule 10b5-1 trading plan. The weighted average sale prices were $50.2568, $51.3830 and $51.9644 per share.
After these indirect sales, BFI Co., LLC reported holding 22,600 shares, while Jack Bendheim directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health reported insider transactions involving an entity associated with its President and CEO, Jack Bendheim. BFI Co., LLC, a ten percent owner, sold a total of 14,080 shares of Class A Common Stock in open-market transactions on February 13 and 18, 2026 under a pre-established Rule 10b5-1 trading plan adopted on May 30, 2025. The weighted average sale prices were around $51–$52 per share, with detailed price ranges disclosed in the footnotes. After these sales, BFI held 36,680 shares, and Bendheim also directly held 16,840 shares. The filing notes that Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Phibro Animal Health insider activity shows that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 72,198 shares of Class A common stock in open-market transactions on February 10–11, 2026. The shares were sold under a pre-established Rule 10b5-1 trading plan adopted by BFI on May 30, 2025, at weighted average prices ranging from about $51.61 to $52.21. Following these indirect sales, BFI continued to hold 50,760 shares, while Bendheim directly held 16,840 shares.